NO20073876L - Pyrazolopyrimidinderivater som mGluR2-antagonister - Google Patents

Pyrazolopyrimidinderivater som mGluR2-antagonister

Info

Publication number
NO20073876L
NO20073876L NO20073876A NO20073876A NO20073876L NO 20073876 L NO20073876 L NO 20073876L NO 20073876 A NO20073876 A NO 20073876A NO 20073876 A NO20073876 A NO 20073876A NO 20073876 L NO20073876 L NO 20073876L
Authority
NO
Norway
Prior art keywords
pyrazolopyrimidine derivatives
derivatives
mglur2 antagonists
preparation
treatment
Prior art date
Application number
NO20073876A
Other languages
English (en)
Inventor
Erwin Goetschi
Silvia Gatti Mcarthur
Juergen Wichmann
Thomas Johannes Woltering
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of NO20073876L publication Critical patent/NO20073876L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Foreliggende oppfinnelse angår pyrazolopyrimidinderivater med formel (I): hvor R1 til R4 og A er som definert i beskrivelsen, en fremgangsmåte for fremstilling derav, anvendelse av dem for behandling eller forhindring av metabotropisk glutamatreseptormedierte lidelser, anvendelse av dem for fremstilling av medikamenter for behandling av slike lidelser og farmasøytiske preparater inneholdende nevnte derivater.
NO20073876A 2005-02-11 2007-07-24 Pyrazolopyrimidinderivater som mGluR2-antagonister NO20073876L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05101027 2005-02-11
PCT/EP2006/000940 WO2006084634A1 (en) 2005-02-11 2006-02-03 Pyrazolo-pyrimidine derivatives as mglur2 antagonists

Publications (1)

Publication Number Publication Date
NO20073876L true NO20073876L (no) 2007-09-10

Family

ID=36090752

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20073876A NO20073876L (no) 2005-02-11 2007-07-24 Pyrazolopyrimidinderivater som mGluR2-antagonister

Country Status (18)

Country Link
US (1) US7361659B2 (no)
EP (1) EP1851225B1 (no)
JP (1) JP4708438B2 (no)
KR (1) KR100968291B1 (no)
CN (1) CN101115755B (no)
AR (1) AR052568A1 (no)
AT (1) ATE512966T1 (no)
AU (1) AU2006212457B2 (no)
BR (1) BRPI0607927A2 (no)
CA (1) CA2597608C (no)
ES (1) ES2365406T3 (no)
IL (1) IL184712A (no)
MX (1) MX2007009106A (no)
NO (1) NO20073876L (no)
RU (1) RU2402553C2 (no)
TW (1) TW200716120A (no)
WO (1) WO2006084634A1 (no)
ZA (1) ZA200706353B (no)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2085398A1 (en) * 2008-02-01 2009-08-05 Merz Pharma GmbH & Co. KGaA Pyrazolopyrimidines, a process for their preparation and their use as medicine
EP2268645B1 (en) * 2008-03-06 2014-11-12 Sanofi Substituted dihydro, trihydro and tetrahydro cycloalkyloxazolopyrimidinones, preparation and use thereof as allosteric modulators of mglur
US8207181B2 (en) 2008-03-06 2012-06-26 Sanofi Substituted dihydro, trihydro and tetrahydro cycloalkyloxazolopyrimidinones, preparation and use thereof
US20130137865A1 (en) 2010-08-11 2013-05-30 Taisho Pharmaceutical Co., Ltd. Heteroaryl-pyrazole derivative
US9447099B2 (en) * 2011-10-04 2016-09-20 Hoffmann-La Roche Inc. Methods for the preparation of 5-[2-[7 (trifluoromethyl)-5-[4-(trifluoromethyl)phenyl]pyrazolo [1,5-A]pyrimidin-3-yl[ethynyl]-2-pyridinamine
AU2012325909B2 (en) * 2011-10-20 2016-06-09 Glaxosmithkline Llc Substituted bicyclic aza-heterocycles and analogues as sirtuin modulators
EP2666775A1 (en) 2012-05-21 2013-11-27 Domain Therapeutics Substituted pyrazoloquinazolinones and pyrroloquinazolinones as allosteric modulators of group II metabotropic glutamate receptors
AU2013336863A1 (en) 2012-10-23 2015-03-19 F. Hoffmann-La Roche Ag MGlu2/3 antagonists for the treatment of autistic disorders
KR20160143853A (ko) 2014-04-23 2016-12-14 에프. 호프만-라 로슈 아게 지적 장애의 치료를 위한 mglu2/3 길항제
JOP20150179B1 (ar) * 2014-08-01 2021-08-17 Janssen Pharmaceutica Nv مركبات 6 ، 7 ثاني هيدرو بيرازولو [ 1، 5 الفا ] بيرازين – 4 (5 يد) – اون واستخدامها كمنظمات الوسترية سلبية لمستقبلات ملجور 2
EP3000814A1 (en) 2014-09-26 2016-03-30 Domain Therapeutics Substituted pyrazoloquinazolinones and pyrroloquinazolinones as allosteric modulators of group II metabotropic glutamate receptors
US20170333435A1 (en) 2014-11-06 2017-11-23 Lysosomal Therapeutics Inc. Substituted imidazo[1,5-a]pyrimidines and their use in the treatment of medical disorders
MX2017005940A (es) 2014-11-06 2018-01-11 Lysosomal Therapeutics Inc Pyrazolo [1, 5-a] pirimidinas sustituidas y su uso en el tratamiento de trastornos médicos.
AU2015342883B2 (en) 2014-11-06 2020-07-02 Bial - R&D Investments, S.A. Substituted pyrrolo(1,2-a)pyrimidines and their use in the treatment of medical disorders
ES2727158T3 (es) 2014-12-03 2019-10-14 Janssen Pharmaceutica Nv Ligandos para PET de mGluR2 radiomarcados
PL236355B1 (pl) * 2015-04-02 2021-01-11 Celon Pharma Spolka Akcyjna Pochodne 7-(morfolin-4-ylo)pirazolo[1,5-α]pirymidyny jako inhibitory kinazy PI3
AU2016374571B2 (en) 2015-12-18 2021-05-06 Janssen Pharmaceutica Nv Radiolabelled mGluR2/3 PET ligands
ES2820823T3 (es) 2015-12-18 2021-04-22 Janssen Pharmaceutica Nv Ligandos PET mGluR2/3 radiomarcados
WO2017176961A1 (en) 2016-04-06 2017-10-12 Lysosomal Therapeutics Inc. Imidazo [1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders
CA3020310A1 (en) 2016-04-06 2017-10-12 Lysosomal Therapeutics Inc. Pyrrolo[1,2-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders
US11192892B2 (en) 2016-04-06 2021-12-07 Bial—R&D Investments, S.A. Substituted pyrazolo[1,5-a]pyrimidines for the treatment of medical disorders
MX2018013529A (es) 2016-05-05 2019-07-04 Lysosomal Therapeutics Inc Imidazo[1,2-b]piridazinas sustituidas, imidazo[1,5-b]piridazinas sustituidas, compuestos relacionados y su uso en el tratamiento de trastornos médicos.
WO2017192931A1 (en) 2016-05-05 2017-11-09 Lysosomal Therapeutics Inc. SUBSTITUTED IMDAZO[1,2-α]PYRIDINES, SUBSTITUTED IMIDAZO[1,2-α]PYRAZINES, RELATED COMPOUNDS, AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS
JP7150343B2 (ja) * 2017-01-09 2022-10-11 フェーノ・セラピューティクス・カンパニー・リミテッド チアゾール誘導体およびその使用
CN111601811B (zh) 2017-11-24 2023-05-05 住友制药株式会社 6,7-二氢吡唑并[1,5-a]吡嗪酮衍生物和其医药用途
WO2020007355A1 (zh) * 2018-07-06 2020-01-09 南京明德新药研发有限公司 噻唑类化合物的晶型及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ330119A (en) 1996-02-07 2000-02-28 Janssen Pharmaceutica Nv Pyrazolopyrimidines as crf receptor antagonists
EP0891978B1 (en) 1997-07-18 2002-03-20 F. Hoffmann-La Roche Ag 5H-Thiazolo (3,2-a) pyrimidine derivatives
WO2000059908A2 (en) * 1999-04-06 2000-10-12 Du Pont Pharmaceuticals Company Pyrazolopyrimidines as crf antagonists
AU2002312788B2 (en) * 2001-04-12 2005-11-10 F. Hoffmann-La Roche Ag Dihydro-benzo [b] [1, 4] diazepin-2-one derivatives as mGluR2 antagonists II
EP1615904B1 (en) * 2003-04-15 2008-02-27 AstraZeneca AB Substituted benzosulphonamides as potentiators of glutamate receptors
US7329662B2 (en) * 2003-10-03 2008-02-12 Hoffmann-La Roche Inc. Pyrazolo-pyridine
RU2378277C2 (ru) * 2004-06-21 2010-01-10 Ф. Хоффманн-Ля Рош Аг Производные пиразолпиримидина

Also Published As

Publication number Publication date
BRPI0607927A2 (pt) 2009-10-20
CA2597608A1 (en) 2006-08-17
AR052568A1 (es) 2007-03-21
KR20070104592A (ko) 2007-10-26
RU2402553C2 (ru) 2010-10-27
WO2006084634A1 (en) 2006-08-17
EP1851225A1 (en) 2007-11-07
CN101115755A (zh) 2008-01-30
AU2006212457B2 (en) 2011-04-14
IL184712A (en) 2013-05-30
CN101115755B (zh) 2013-01-16
US7361659B2 (en) 2008-04-22
CA2597608C (en) 2013-12-24
ES2365406T3 (es) 2011-10-04
JP4708438B2 (ja) 2011-06-22
EP1851225B1 (en) 2011-06-15
IL184712A0 (en) 2007-12-03
JP2008530042A (ja) 2008-08-07
US20060183756A1 (en) 2006-08-17
ZA200706353B (en) 2009-09-30
RU2007128624A (ru) 2009-03-20
KR100968291B1 (ko) 2010-07-07
ATE512966T1 (de) 2011-07-15
AU2006212457A1 (en) 2006-08-17
TW200716120A (en) 2007-05-01
MX2007009106A (es) 2007-09-11

Similar Documents

Publication Publication Date Title
NO20073876L (no) Pyrazolopyrimidinderivater som mGluR2-antagonister
NO20074592L (no) Acetylenyl-pyrazolo-pyrimidinderivater som mGluR2-antagonister
NO20074258L (no) Pyridin-2-karboksamidderivater som MGLUR5 antagonister
NO20092342L (no) Azaspiroderivativater
NO20072978L (no) Nye betuinderivater, preparat derav og anvendelse derav
NO20045301L (no) Substituert 1,3-diphenylprop-2-en-1-one derivat, fremstilling og anvendelse derav.
NO20083919L (no) Pyridin- og pyrimidinderivater som mGluR2-antagonister
NO20070339L (no) 1-aza-bicyklo[3 3.1]nonaner
NO20072784L (no) Pyridenkarboksamidderivater for anvendelse som anticancer midler
NO20070224L (no) 2-karbamid-4-fenyltiazolderivater, fremstilling og terapeutisk anvendelse derav
NO20062583L (no) Difenylazetidinonderivater med kolesterolabsorpsjonsinhiberende aktivitet
NO20070199L (no) Substituerte kinazoloner som anti-kreftmidler
NO20062591L (no) Difenylazetidinonderivater med kolesterolabsorpsjonsinhiberende aktivitet
EA200801909A1 (ru) Соединения пиридина для лечения заболеваний, опосредованных действием простагландина
NO20071703L (no) Kinazolinderivater
NO20060001L (no) Nye P2X7-reseptorantagonister og deres anvendelse
NO20062923L (no) Nye benzofuranderivater som kan anvendes i forebygging eller behandling av 5-HT6 reseptorrelatert forstyrrelse
NO20080408L (no) Azaindazolforbindelser og anvendelse derav
NO20062824L (no) 1,3-Difenylprop-2-en-1-on-avledete forbindelser, fremgangsmater for fremstilling derav, samt anvendelse av samme
NO20076197L (no) Nye 2-azetidinonderivater anvendbare i behandling av hyperlipidemiske tilstander
WO2009010871A3 (en) Pyrazole derivatives as antagonists of adenosine a3 receptor
NO20073059L (no) 2,3,4,9-tetrahydro-1h-carbazole derivatives as crth2 receptor antagonists
NO20076195L (no) Nye 2-azetidinonderivater for behandling av hyperlipidemiske sykdommer
MY147677A (en) Piperazinyl derivatives useful in the treatment of gpr38 receptor mediated diseases
TW200640863A (en) Compounds which potentiate glutamate receptor and uses thereof in medicine

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application